| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1014209630 |
| P356 | DOI | 10.2165/00003088-198712060-00001 |
| P698 | PubMed publication ID | 3301149 |
| P50 | author | Robin Ferner | Q37841555 |
| P2093 | author name string | S Chaplin | |
| P2860 | cites work | Radioimmunoassay of Glibenclamide | Q28319020 |
| Metabolic fate of tolazamide in man and in the rat | Q28327045 | ||
| Antidiabetic Drugs After the University Group Diabetes Program (UGDP) | Q34020665 | ||
| Pharmacodynamic aspects of tolbutamide, glibenclamide, glibornuride and glisoxepide. I. Dose response relations and repeated administration in diabetic subjects | Q34226184 | ||
| Interaction of glipizide with human serum albumin | Q34648531 | ||
| Glipizide: a review of its pharmacological properties and therapeutic use. | Q34693555 | ||
| Pharmacokinetics of glipizide in man: Influence of renal insufficiency | Q34700096 | ||
| Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus. | Q34708892 | ||
| Oral hypoglycaemic agents. An update | Q34708953 | ||
| Correlation between serum concentration and hypoglycemic effect of chlorpropamide in man. | Q34711157 | ||
| Effect of sulfonylurea treatment on in vivo insulin secretion and action in patients with non-insulin-dependent diabetes mellitus | Q34712727 | ||
| Comparative single-dose kinetics and effects of four sulfonylureas in healthy volunteers. | Q34712831 | ||
| Effect of prolonged glyclazide treatment on blood glucose and plasma insulin responses in obese patients with maturity-onset diabetes | Q34714225 | ||
| The regulation of glucose-induced insulin secretion by pre-stimulus glucose level and tolbutamide in normal man | Q70189192 | ||
| Differential effects of tolbutamide on first and second phase insulin secretion in noninsulin-dependent diabetes mellitus | Q70189959 | ||
| Effects of tolbutamide on insulin binding to isolated fat cells of the rat | Q70245050 | ||
| UK prospective study of therapies of maturity-onset diabetes. I. Effect of diet, sulphonylurea, insulin or biguanide therapy on fasting plasma glucose and body weight over one year | Q70275000 | ||
| Pharmacokinetic disposition of 14C-glyburide in patients with varying renal function | Q70277380 | ||
| Effects of total plasma concentration and age on tolbutamide plasma protein binding | Q70283823 | ||
| Effect of middle-term gliclazide treatment on insulin secretion in non-insulin dependent diabetics | Q70353327 | ||
| Effect of activated charcoal on absorption of tolbutamide and valproate in man | Q70430409 | ||
| Pharmacokinetics and biotransformation of chlorpropamide in man | Q70438569 | ||
| Glibenclamide-associated hypoglycaemia: a report on 57 cases | Q70444886 | ||
| Bioavailability, pharmacokinetics and effects of glipizide in type 2 diabetics | Q70449262 | ||
| [Pharmacodynamics and pharmacokinetics of 2 glibenclamide preparations in type 2 diabetes. Intraindividual double-blind comparison of Euglucon 5 (HB 419) and Euglucon N (HB 420)] | Q70466069 | ||
| Bioavailability of tolazamide from tablets: comparison of in vitro and in vivo results | Q70606167 | ||
| Nonenzymatic glucosylation of human serum albumin and its influence on binding capacity of sulfonylureas | Q70639248 | ||
| Diabetes in identical twins. A study of 200 pairs | Q70659026 | ||
| Influence of blood proteins on biomedical analysis. III. Pharmacokinetics and protein binding of gliclazide | Q70947766 | ||
| Long-term comparative trial of glibenclamide and chlorpropamide in diet-failed, maturity-onset diabetics | Q71154394 | ||
| Blood Sugar Lowering Effects of Chlorpropamide and Tolbutamide: A Double Blind Cooperative Study | Q71158862 | ||
| The effects of long-term acetohexamide treatment on pancreatic islet cell function in maturity-onset diabetes | Q71192166 | ||
| Wide variation in serum chlorpropamide concentration in outpatients | Q71359366 | ||
| The effect of food on the bioavailability and pharmacodynamics of tolbutamide in diabetic patients | Q71438853 | ||
| Hormonal and metabolic effects of chlorpropamide, glibenclamide and placebo in a cross-over study in diabetics not controlled by diet alone | Q71538077 | ||
| High-performance liquid column and thin-layer chromatographic determination of human serum glibenclamide at therapeutic levels | Q71585827 | ||
| Studies in Patients with Chlorpropamide-Induced Hypoglycemia | Q71607183 | ||
| Determination of glyburide in human serum by liquid chromatography with fluorescence detection | Q71617386 | ||
| Pharmacokinetics of intravenous glibenclamide investigated by a high performance liquid chromatographic assay | Q71619196 | ||
| Chlorpropamide and glibenclamide serum concentrations in hospitalized patients | Q71627036 | ||
| Tissue distribution and metabolism of drugs VI: Effect of second drugs on pancreatic distribution and insulin-releasing activity of sulfonylureas in perfused rat pancreas | Q72128006 | ||
| Phenformin-induced lacticacidosis associated with impaired debrisoquine hydroxylation | Q72464555 | ||
| Tolbutamide, glucose, calcium, and somatostatin secretion | Q72520755 | ||
| Glibenclamide is exceptional among hypoglycaemic sulphonylureas in accumulating progressively in β-cell-rich pancreatic islets | Q72809187 | ||
| Relation to quantity of sulfonylurea by mouth to the hypoglycemic response in normal human subjects | Q74258399 | ||
| Tolbutamide: a double-blind study of its effect in diabetes | Q74665114 | ||
| Evaluation of duration of action and clinical effectiveness of acetohexamide | Q76496331 | ||
| METABOLISM OF ANTIDIABETIC SULFONYLUREAS IN MAN. I. BIOLOGICAL HALF-LIVES OF THE P-ACETYLBENZENESULFONYLUREAS, U-18536 AND ACETOHEXAMIDE AND THEIR METABOLITES | Q78233596 | ||
| SERUM CONCENTRATION AND URINARY EXCRETION OF ORAL SULFONYLUREA COMPOUNDS: RELATION TO DIABETIC CONTROL | Q78384597 | ||
| FAILURE OF PROLONGED SULFONYLUREA ADMINISTRATION TO ENHANCE INSULOGENIC RESPONSE TO GLYCEMIC STIMULUS | Q78457831 | ||
| Relative potencies of chlorpropamide and tolbutamide in man | Q78584795 | ||
| Metabolic studies of chlorpropamide in normal men and in diabetic subjects | Q78584852 | ||
| A comparison of the acute hypoglycemic potencies of tolbutamide and chlorpropamide | Q78584856 | ||
| Studies with chlorpropamide in diabetic patients | Q78584861 | ||
| A new high potency antidiabetic sulfonylurea [N-(1-hexahydro-1-azepinyl)-N'-p-tolyl-sulfonylurea] | Q78928774 | ||
| Comparative pharmacology of the sulfonylureas | Q79058711 | ||
| Comparison of acute hypoglycemic potencies of tolbutamide and chlorpropamide | Q79201277 | ||
| Influence of food and age on the single-dose kinetics and effects of tolbutamide and chlorpropamide | Q34714299 | ||
| Influence of food intake on the absorption and effect of glipizide in diabetics and in healthy subjects | Q34714382 | ||
| Clinical pharmacology of sulphonylurea hypoglycaemic agents: part 1. | Q34714526 | ||
| Clinical pharmacology of sulphonylurea hypoglycaemic agents: part 2. | Q34714607 | ||
| Comparison of the pharmacokinetics of glipizide and glibenclamide in man | Q34728399 | ||
| Chlorpropamide-induced hypoglycemia: successful treatment with diazoxide | Q34743054 | ||
| A comparison of the effects of tolazamide and tolbutamide upon blood glucose and serum insulin and lipid levels in diabetic subjects | Q35918796 | ||
| Plasma concentrations, bioavailability and dissolution of chlorpropamide | Q39144404 | ||
| Influence of treatment with diet alone on oral glucose-tolerance test and plasma sugar and insulin levels in patients with maturity-onset diabetes mellitus | Q39329226 | ||
| Why is there still disagreement over insulin secretion in non-insulin-dependent diabetes? | Q39481343 | ||
| "First" and "second" generation sulfonylureas: distinction or difference? (author's transl) | Q39613410 | ||
| Clinical pharmacology of oral antidiabetic agents (first of two parts). | Q39617275 | ||
| Des 4-trans-hydroxy-glibenclamide show hypoglycemic activity? | Q39664298 | ||
| Effect of two sulphonylureas on the dose kinetics of glucose-induced insulin release in normal and diabetic subjects | Q39674591 | ||
| Glibenclamide and glipizide in maturity onset diabetes. A double-blind cross-over study | Q39697250 | ||
| Comparative study of the hypoglycaemic and antilipolytic effects of four antidiabetic agents administered i.v | Q39783928 | ||
| Metformin: a review of its pharmacological properties and therapeutic use | Q39812475 | ||
| Glipizide: a second-generation sulfonylurea hypoglycemic agent. Pharmacology, pharmacokinetics and clinical use. | Q39847061 | ||
| Sulfonylureas in the treatment of diabetes mellitus--1985. | Q39847398 | ||
| Metformin and the sulphonylureas: the comparative risk | Q39850311 | ||
| Drug-induced hypoglycemia. A review based on 473 cases | Q39956038 | ||
| Stimulus-secretion coupling in the pancreatic B-cell: concluding remarks | Q40078304 | ||
| The chlorpropamide alcohol flush | Q40184344 | ||
| Interaction of sulfonylurea with the pancreatic B-cell | Q40214406 | ||
| Clinical pharmacokinetics of sulphonylurea hypoglycaemic drugs | Q40307292 | ||
| The pathogenesis of non-insulin-dependent diabetes: an update | Q40330569 | ||
| Effects of Glipizide and Food Intake on the Blood Levels of Glucose and Insulin in Diabetic Patients | Q40874614 | ||
| Behaviour of glibenclamide on repeated administration to diabetic patients | Q41223560 | ||
| Absorption of glibenclamide from different sites of the gastro-intestinal tract | Q41490907 | ||
| Chronic chlorpropamide therapy of noninsulin-dependent diabetes augments basal and stimulated insulin secretion by increasing islet sensitivity to glucose | Q41618502 | ||
| Genetic polymorphism of phenformin 4-hydroxylation | Q41621757 | ||
| The control of 86Rb efflux from rat isolated pancreatic islets by the sulphonylureas tolbutamide and glibenclamide | Q41743596 | ||
| Massive glibenclamide overdose without hypoglycaemia in a man with diabetes after partial pancreatectomy | Q42114512 | ||
| Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush | Q42259329 | ||
| Improved effect of tolbutamide when given before food in patients on long-term therapy. | Q42531562 | ||
| Elevation of the number of cell-surface insulin receptors and the rate of 2-deoxyglucose uptake by exposure of 3T3-L1 adipocytes to tolbutamide | Q42813909 | ||
| The sulphonylurea receptor may be an ATP-sensitive potassium channel. | Q44062075 | ||
| Metabolism, Blood Levels and Rate of Excretion of Acetohexamide in Human Subjects | Q44559212 | ||
| Pharmacodynamic aspects of two sulphonylurea derivatives glipizide and glibenclamide. | Q44682369 | ||
| Sulphonylurea therapy doubles B-cell response to glucose in type 2 diabetic patients. | Q51636422 | ||
| Effects of glyburide therapy on lipoproteins in non-insulin-dependent diabetes mellitus. | Q51636953 | ||
| The 24-hour effects of glyburide and chlorpropamide after chronic treatment of type II diabetic patients. | Q51638367 | ||
| Pharmacokinetics and metabolic effects of glibenclamide and glipizide in type 2 diabetics. | Q51639833 | ||
| Insulin Therapy in Obese, Non-insulin-dependent Diabetes Induces Improvements in Insulin Action and Secretion that Are Maintained for Two Weeks After Insulin Withdrawal | Q51642223 | ||
| Plasma levels of glibenclamide in diabetic patients during its routine clinical administration determined by a specific radioimmunoassay. | Q51645957 | ||
| Modulation by IBMX, fasting and experimental diabetes of glibenclamide-induced islet hormone release from the perfused rat pancreas | Q51647683 | ||
| Improved effect of glibenclamide on administration before breakfast. | Q51652920 | ||
| Comparison of chlorpropamide and glibenclamide treatment of maturity-onset diabetes: control assessed by fasting plasma glucose concentrations. | Q51655604 | ||
| The antidiabetic effect and pharmacokinetic properties of glipizide. Comparison of a single dose with divided dose regime. | Q51656574 | ||
| Irregular drug intake and serum chlorpropaminde concentrations. | Q51658262 | ||
| Serum glibenclamide in diabetic patients, and influence of food on the kinetics and effects of glibenclamide. | Q51660771 | ||
| Serum tolbutamide and chlorpropamide concentrations in patients with diabetes mellitus | Q51665590 | ||
| Plasma insulin and glucose levels in maturity onset diabetics treated with chlorpropamide | Q51666852 | ||
| GLYCODIAZINE IN DIABETES MELLITUS: A CLINICAL TRIAL. | Q53032288 | ||
| Pharmacokinetics and pharmacodynamics as well as metabolism following orally and intravenously administered C14-glipizide, a new antidiabetic | Q53739870 | ||
| B CELL HYPERFUNCTION AFTER LONG-TERM SULFONYLUREA TREATMENT | Q53761645 | ||
| Effect of food and tablet age on relative bioavailability and pharmacodynamics of two tolbutamide products. | Q54047699 | ||
| Impaired effect of sulfonylurea following increased dosage. | Q54524303 | ||
| Disposition of metformin (N,N-dimethylbiguanide) in man. | Q55062974 | ||
| Blood Glucose Variations and Clinical Experience with Glibenclamide in Diabetes Mellitus | Q55445535 | ||
| Human pharmacokinetics and metabolism of 14C-labeled gliquidone (AR-DF 26) | Q66902392 | ||
| Pharmacogenetics of tolbutamide metabolism in humans | Q67017361 | ||
| Pharmacodynamic aspects of tolbutamide, glibenclamide, glibornuride, and glisoxepide. II. Repeated administration in combination with glucose | Q67252362 | ||
| Effects of charcoal, sodium bicarbonate, and ammonium chloride on chlorpropamide kinetics | Q67265594 | ||
| Epidemiology of adverse drug reactions to phenformin and metformin | Q67365612 | ||
| Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole | Q67693881 | ||
| Dose-response relationships of tolbutamide and glibenclamide in diabetes mellitus | Q68348428 | ||
| Effects of tolazamide and exogenous insulin on insulin action in patients with non-insulin-dependent diabetes mellitus | Q68874169 | ||
| Type II diabetes: insulin versus oral agents | Q68874178 | ||
| Studies on the bioavailability of glibenclamide | Q69373524 | ||
| The stimulatory effect on insulin secretion in long-term tolbutamide treatment. Immunological determinations of urinary- and serum insulin | Q69461147 | ||
| Inhibition of tolbutamide elimination by cimetidine but not ranitidine | Q69492329 | ||
| Effect of chlorpropamide treatment on insulin secretion in diabetics: its relationship to the hypoglycemic effect | Q69519256 | ||
| [Hypoglycemia during treatment with sulfonylurea preparations] | Q69630613 | ||
| Insulinotropic potency of glipizide in vitro | Q69645416 | ||
| The bioavailability in man of marketed brands of chlorpropamide | Q69816710 | ||
| Longitudinal evaluation of the effects of sulfonylurea therapy in subjects with type II diabetes mellitus | Q69967177 | ||
| Once-daily use of glyburide | Q69967189 | ||
| Effect of short and long term chlorpropamide treatment of insulin release and blood-glucose | Q70022224 | ||
| [The relatively frequent incidence of severe sulfonylurea-induced hypoglycemia in the last 25 years in Switzerland. Results of 2 surveys in Switzerland in 1969 and 1984] | Q70037443 | ||
| Metabolic and clinical effects of glibenclamide | Q70125164 | ||
| P433 | issue | 6 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| pharmacodynamics | Q725307 | ||
| P304 | page(s) | 379-401 | |
| P577 | publication date | 1987-06-01 | |
| P1433 | published in | Clinical Pharmacokinetics | Q5133788 |
| P1476 | title | The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs | |
| P478 | volume | 12 |
| Q40520287 | Antihyperglycaemic agents. Drug interactions of clinical importance |
| Q34480831 | Bench-to-bedside review: Antidotal treatment of sulfonylurea-induced hypoglycaemia with octreotide |
| Q40587499 | Comparative tolerability profiles of oral antidiabetic agents |
| Q35210475 | Contributions of human cytochrome P450 enzymes to glyburide metabolism |
| Q40882757 | Drug interactions in diabetic patients. The risk of losing glycemic control |
| Q42573118 | Drug-drug Interaction between Pravastatin and Gemfibrozil (Antihyperlipidemic) with Gliclazide (Antidiabetic) in Rats |
| Q36350528 | Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance |
| Q34734418 | Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects |
| Q67864038 | Efficacy of gliclazide in comparison with other sulphonylureas in the treatment of NIDDM |
| Q51993910 | Hemiparesis and altered mental status in a child after glyburide ingestion. |
| Q37039960 | Hypoglycaemic and anti-hyperglycaemic drugs for the control of diabetes |
| Q37071750 | Impact of therapeutic advances on hypoglycaemia in type 2 diabetes |
| Q51553487 | In vitro and in vivo antioxidant properties of gliclazide. |
| Q77883722 | Inhibition of tumor necrosis factor-alpha with anti-diabetic agents |
| Q41816239 | Interactions of rosiglitazone and anti-arrhythmic drugs in animal model |
| Q73779390 | Lack of interaction between tolcapone and tolbutamide in healthy volunteers |
| Q77591261 | Management of antidiabetic medications in overdose |
| Q74079090 | Microvascular permeability with sulfonylureas in normal and diabetic hamsters |
| Q41277363 | Oral antidiabetic drug use in the elderly |
| Q70222704 | Oral hypoglycemic agents |
| Q34398484 | Pharmacokinetic and pharmacodynamic studies of glibenclamide in non-insulin dependent diabetes mellitus |
| Q38631248 | Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update |
| Q36830742 | Pharmacokinetics and pharmacodynamics of the hydroxymetabolite of glimepiride (Amaryl) after intravenous administration |
| Q41149331 | Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency |
| Q54532475 | Possible protein binding displacement interaction between glibenclamide and metolazone. |
| Q40816622 | Problems and pitfalls of sulphonylurea therapy in older patients |
| Q46813177 | Protective effects of glurenorm (gliquidone) treatment on the liver injury of experimental diabetes |
| Q34503808 | Repaglinide pharmacokinetics in healthy young adult and elderly subjects |
| Q74506081 | Sulfonylurea effects on acid and pepsinogen secretion in isolated rabbit gastric glands |
| Q38618657 | Sulphonylurea antidiabetic drugs. An update of their clinical pharmacology and rational therapeutic use. |
| Q41063243 | Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing? |
| Q42734557 | Sulphonylureas and hypoglycaemia |
| Q39578390 | Sulphonylureas in the treatment of non-insulin-dependent diabetes |
| Q36660303 | The Management of Diabetes Mellitus in Older Individuals |
| Q43777182 | The effect of Glurenorm (gliquidone) on lenses and skin in experimental diabetes |
| Q42007518 | The effect of cholestyramine and activated charcoal on glipizide absorption |
| Q72877062 | The effect of hyperglycaemia on the absorption of glibenclamide in patients with non-insulin-dependent diabetes mellitus |
| Q74079086 | The effects of gliclazide and other sulfonylureas on low-density lipoprotein oxidation in vitro |
| Q36618105 | Treatment of sulfonylurea and insulin overdose |
| Q74639903 | When does hypoglycemia develop after sulfonylurea ingestion? |
Search more.